EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Liu, G.
Cheng, D.
Le Maitre, A.
Liu, N.
Chen, Z.
Seymour, L.
Ding, K.
Shepherd, F. A.
Tsao, M. S.
机构：
[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[2] Queens Univ, Kingston, ON, Canada
[3] NCIC Clin Trials Grp, Kingston, ON, Canada
[4] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7538
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Genetic Polymorphisms as Prognostic/Predictive Biomarkers of Single-Agent Erlotinib Therapy in NCIC-CTG BR.21 Non-Small Cell Lung Cancer (NSCLC) Trial
    Liu, Geoffrey
    Cheng, Dangxiao
    Le Maitre, Aurelie
    Liu, Ni
    Chen, Zhuo
    Seymour, Lesley
    Ding, Keyue
    Shepherd, Frances
    Tsao, Ming
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S207 - S207
  • [2] Comparison of e-cadherin IHC status with clinical outcomes from erlotinib in the non-small cell lung cancer (NSCLC) clinical trial NCIC CTG BR.21
    Richardson, Frank
    Young, David
    Wolf, Julie
    Sennello, Gina
    Wacker, Bret
    Davies, Angela
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S504 - S505
  • [3] Baseline TGF-α and amphiregulin levels in non small cell lung cancer (NSCLC) patients treated with erlotinib or placebo in the NCIC Clinical Trials Group (NCIC CTG) BR.21 clinical trial
    Bradbury, Penelope A.
    Addison, Christina L.
    Goss, Glenwood
    Shepherd, Frances A.
    Seymour, Lesley
    Le Maitre, Aurelie
    Ding, Keyue
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S537 - S538
  • [4] Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: Time course and correlation with survival
    Perez-Soler, Roman
    Leon, Larry
    Wojtowicz-Praga, Slawomir
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial
    Carbone, David P.
    Ding, Keyue
    Roder, Heinrich
    Grigorieva, Julia
    Roder, Joanna
    Tsao, Ming-Sound
    Seymour, Lesley
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : 1653 - 1660
  • [6] National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. A placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC)
    Ciuleanu, T. E.
    Shepherd, F.
    Pereira, J.
    Tan, E. H.
    Hirsch, V.
    Thongprasert, S.
    Bezjak, A.
    Ding, K.
    Ptaszynski, M.
    Seymour, L.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [7] Symptom response in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib: Quality of life analysis of the NCICCTG BR.21 trial.
    Bezjak, A
    Shepherd, F
    Tu, D
    Clark, G
    Santabarbara, P
    Pater, J
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 625S - 625S
  • [8] Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
    Kim, Seung Tae
    Sung, Jae Sook
    Jo, Uk Hyun
    Park, Kyong Hwa
    Shin, Sang Won
    Kim, Yeul Hong
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [9] CAN MUTATIONS OF EGFR AND KRAS OF SERUM BE PREDICTIVE AND PROGNOSTIC MARKERS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)?
    Kim, S. T.
    Kim, Y. H.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S66 - S66
  • [10] Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
    Seung Tae Kim
    Jae Sook Sung
    Uk Hyun Jo
    Kyong Hwa Park
    Sang Won Shin
    Yeul Hong Kim
    Medical Oncology, 2013, 30
12345